ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,070.55
      1.20%
      US Tech 100
      17,100.00
      2.07%
      Dow Jones
      38,503.69
      0.69%
      Brent Oil
      87.505
      -0.07%
      Bitcoin
      66,569.38
      0.24%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Arvinas Inc (ARVN)

      7. Arvinas Inc (ARVN) News

      ARVN Arvinas Inc

      34.00
      -0.90 (-2.58%)
      Apr 23 2024 - Closed
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Arvinas Inc ARVN NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      -0.90 -2.58% 34.00 20:00:00
      Open Price Low Price High Price Close Price Prev Close
      34.86 33.872 35.58 34.00 34.90
      more quote information »

      Recent News

      Date Time Source Heading
      4/11/202407:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
      3/18/202416:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
      3/04/202407:00GLOBEArvinas to Participate in Upcoming Investor Conferences
      2/27/202418:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/27/202418:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/27/202418:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/27/202418:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/27/202416:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
      2/27/202407:02EDGAR2Form 8-K - Current report
      2/27/202407:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
      2/20/202416:06EDGAR2Form 8-K - Current report
      2/20/202416:05GLOBEArvinas Announces Chief Financial Officer Transition
      2/20/202407:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
      2/14/202408:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
      2/13/202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/06/202406:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
      2/01/202416:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
      1/16/202417:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
      1/16/202416:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
      1/08/202416:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/08/202407:45EDGAR2Form 8-K - Current report
      12/08/202309:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
      12/06/202307:01EDGAR2Form 8-K - Current report
      12/05/202322:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
      12/05/202313:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
      11/28/202317:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
      11/27/202307:11EDGAR2Form 8-K - Current report
      11/27/202307:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
      11/07/202317:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
      11/07/202316:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      11/07/202307:03EDGAR2Form 8-K - Current report
      11/07/202307:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
      11/02/202307:00GLOBEArvinas to Participate in Upcoming Investor Conferences
      10/23/202308:30EDGAR2Form 8-K - Current report
      10/22/202307:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
      10/18/202307:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
      10/15/202318:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
      10/15/202318:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
      9/01/202307:00GLOBEArvinas to Participate in Upcoming Investor Conferences
      8/14/202317:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      8/08/202316:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      8/08/202307:03EDGAR2Form 8-K - Current report
      8/08/202307:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
      7/31/202316:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
      7/06/202309:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
      6/15/202316:30GLOBEArvinas Announces Changes to its Board of Directors
      6/08/202307:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
      6/05/202307:00GLOBEArvinas to Participate in Upcoming Investor Conferences
      5/08/202307:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
      5/05/202307:00GLOBEArvinas Reports First Quarter 2023 Financial Results and..

      Your Recent History

      NASDAQ
      ARVN
      Arvinas
      Delayed Upgrade Clock